|
Zitat:" Following a capital reorganization of Medreleaf that was completed prior to, and in connection with, the closing of the IPO and described in the Prospectus, immediately prior to the closing of the IPO, Raymond Leach owned and controlled, indirectly through Rayray Investments Inc. ("Rayray"), 12,509,479 Common Shares, representing approximately 15.3% of the issued and outstanding Common Shares......In connection with the closing of the IPO, Medreleaf issued and sold 8,494,742 Common Shares from treasury and the Selling Shareholders sold an aggregate of 2,105,258 Common Shares, of which 342,322 Common Shares were sold by Rayray, all at a price of $9.50 per Common Share (for gross proceeds to Rayray of $3,252,059). Immediately after the closing of the IPO, Raymond Leach owned and controlled, indirectly through Rayray, 12,167,157 Common Shares, representing approximately 13.5% of the issued and outstanding Common Shares... Except as set out in this press release, Raymond Leach intends to hold the Common Shares owned and controlled by him for investment purposes. Raymond Leach will evaluate his investment in Medreleaf from time to time and, except as provided herein, may, based on such evaluation, market conditions and other circumstances, acquire further Common Shares or other securities of Medreleaf or dispose of his holdings of securities of Medreleaf.....In connection with the IPO, Rayray entered into a lock-up agreement with GMP pursuant to which Rayray agreed, subject to certain exceptions, not to directly or indirectly offer, sell or otherwise dispose of, without the prior consent of GMP (on behalf of the Underwriters), any securities of Medreleaf for a period of: (a) 180 days following Closing, with respect to one-half of the securities of Medreleaf held by Rayray.."ENDE Zitat
Source:https://www.stockwatch.com/News/...LEAF-2478803&symbol=LEAF®ion=C
|
Thread abonnieren
